The Cancer Letter

Inside information on cancer research and drug development

Guest Editorial

OCE’s Project 5 in 5 seeks to inspire pragmatic innovation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

If the FDA Oncology Center of Excellence (OCE) began an “innovation challenge” in oncology drug development, what would that look like? 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Steven C. Cunningham, MD, MLA, FACS
Clinical reviewer, Gastrointestinal Cancers Team, Division of Oncology 3, CDER, FDA
Donna R. Rivera, PharmD, MS
Associate director, Pharmacoepidemiology and Oncology RWE, Oncology Center of Excellence, FDA
Richard Pazdur, MD
Director, Oncology Center of Excellence, FDA
Kelly J. Norsworthy, MD
Associate director, Research Mentorship, Oncology Center of Excellence, FDA
Jennifer Gao, MD
Associate director, Education, Oncology Center of Excellence, FDA
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

FDA accepts BLA for subcutaneous Opdivo

FDA has accepted the Bristol Myers Squibb’s Biologics License Application for the subcutaneous formulation of Opdivo (nivolumab) co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20)—herein referred to as “subcutaneous nivolumab”—across all previously approved adult, solid tumor Opdivo indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib. 
Byline
Steven C. Cunningham, MD, MLA, FACS
Clinical reviewer, Gastrointestinal Cancers Team, Division of Oncology 3, CDER, FDA
Donna R. Rivera, PharmD, MS
Associate director, Pharmacoepidemiology and Oncology RWE, Oncology Center of Excellence, FDA
Richard Pazdur, MD
Director, Oncology Center of Excellence, FDA
Kelly J. Norsworthy, MD
Associate director, Research Mentorship, Oncology Center of Excellence, FDA
Jennifer Gao, MD
Associate director, Education, Oncology Center of Excellence, FDA
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account